Pacebo-controlled, double-blind, randomised phase II study with crossover-design investigating the modulatory effects of intranasal Oxytocin on social cognition in patients with Autism-Spectrum-Disorder - Social Cognition-Autism-Oxytocin

Trial Profile

Pacebo-controlled, double-blind, randomised phase II study with crossover-design investigating the modulatory effects of intranasal Oxytocin on social cognition in patients with Autism-Spectrum-Disorder - Social Cognition-Autism-Oxytocin

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 May 2017

At a glance

  • Drugs Oxytocin (Primary)
  • Indications Asperger syndrome; Autistic disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Apr 2017 Status changed from not yet recruiting to recruiting.
    • 15 Sep 2016 New trial record
    • 12 Sep 2016 Planned initiation date changed from 23 May 2016 to 30 Oct 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top